CSIR CIMAP AROMA | Compound Details

Warfarin Details

: IUPAC Name

4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one

:Chemical Class

Ketone

:CAS Registry Number

81-81-2

:Description

:Fragrance Type

Physical and Chemical properties

PUBCHEM ID	54678486
Molecular Weight (g/mol)	308.328
Molecular Formula	C19H16O4
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	4
Rotatable Bond Count	4
IUPAC Name	4-hydroxy-3-(3-oxo-1-phenylbutyl)chromen-2-one
Canonical SMILES	CC(=O)CC(c1ccccc1)c3c(O)c2ccccc2oc3=O
PUBCHEM IUPAC INCHIKEY	PJVWKTKQMONHTI-UHFFFAOYSA-N
Solubility Level	3
Vapour Pressure	-7.486

Absorption and Metabolism information

XLOGP3 AA
CACTVS TPSA	63.6
BBB Level	2
Absorption Level	0
EXT PPB#Prediction	1
AlogP98	2.827
EXT CYP2D6#Prediction	1

Toxicological Information

Mouse Female FDA	Non-Carcinogen
Mouse Male FDA	Single-Carcinogen
Rat Female FDA	Non-Carcinogen
Rat Male FDA	Non-Carcinogen
Ames Prediction	Non-Mutagen
Developmental / Reproductive Toxicity	Non-Toxic
Rat Oral LD50	0.337299 g/kg_body_weight
Ocular Irritancy	Mild
Hepatotoxic#Prediction	1
Effected Human Genes

Ecological Information

Aerobic Biodegradability Prediction	Degradable

Hazard(s) Identification

Physical hazards	not classified
Health hazards	None
Environmental hazards	not classified

About Table Headings

Compound Biological Activity

Serial No.	Cas No	Gene Symbol	Organism	Interaction	Interaction Actions	PubMed Id
1	81-81-2	CYP2C9	Homo sapiens	10-hydroxywarfarin binds to and results in decreased activity of CYP2C9 protein	affects^binding\|decreases^activity	20429590
2	81-81-2	CYP2C9	Homo sapiens	[10-hydroxywarfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP2C9 mRNA	affects^binding\|increases^activity\|increases^expression	20735727
3	81-81-2	CYP3A4	Homo sapiens	[10-hydroxywarfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA	affects^binding\|increases^activity\|increases^expression	20735727
4	81-81-2	NR1I2	Homo sapiens	10-hydroxywarfarin binds to and results in increased activity of NR1I2 protein	affects^binding\|increases^activity	20735727
5	81-81-2	UGT2B7	Homo sapiens	10-hydroxywarfarin binds to and results in decreased activity of UGT2B7 protein	affects^binding\|decreases^activity	25393417
6	81-81-2	UGT2B7	Homo sapiens	[10-hydroxywarfarin binds to and results in decreased activity of UGT2B7 protein] which results in decreased glucuronidation of Zidovudine	affects^binding\|decreases^activity\|decreases^glucuronidation	25393417
7	81-81-2	CYP2C9	Homo sapiens	4'-hydroxywarfarin binds to and results in decreased activity of CYP2C9 protein	affects^binding\|decreases^activity	20429590
8	81-81-2	CYP2C9	Homo sapiens	[4'-hydroxywarfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP2C9 mRNA	affects^binding\|increases^activity\|increases^expression	20735727
9	81-81-2	CYP3A4	Homo sapiens	[4'-hydroxywarfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA	affects^binding\|increases^activity\|increases^expression	20735727
10	81-81-2	NR1I2	Homo sapiens	4'-hydroxywarfarin binds to and results in increased activity of NR1I2 protein	affects^binding\|increases^activity	20735727
11	81-81-2	UGT2B7	Homo sapiens	4'-hydroxywarfarin binds to and results in decreased activity of UGT2B7 protein	affects^binding\|decreases^activity	25393417
12	81-81-2	UGT2B7	Homo sapiens	[4'-hydroxywarfarin binds to and results in decreased activity of UGT2B7 protein] which results in decreased glucuronidation of Zidovudine	affects^binding\|decreases^activity\|decreases^glucuronidation	25393417
13	81-81-2	CYP2C9	Homo sapiens	6-hydroxywarfarin results in decreased activity of CYP2C9 protein	decreases^activity	20429590
14	81-81-2	UGT2B7	Homo sapiens	6-hydroxywarfarin binds to UGT2B7 protein	affects^binding	25393417
15	81-81-2	CYP2C9	Homo sapiens	7-hydroxywarfarin results in decreased activity of CYP2C9 protein	decreases^activity	20429590
16	81-81-2	UGT2B7	Homo sapiens	7-hydroxywarfarin binds to and results in decreased activity of UGT2B7 protein	affects^binding\|decreases^activity	25393417
17	81-81-2	UGT2B7	Homo sapiens	[7-hydroxywarfarin binds to and results in decreased activity of UGT2B7 protein] which results in decreased glucuronidation of Zidovudine	affects^binding\|decreases^activity\|decreases^glucuronidation	25393417
18	81-81-2	CYP2C9	Homo sapiens	8-hydroxywarfarin results in decreased activity of CYP2C9 protein	decreases^activity	20429590
19	81-81-2	UGT2B7	Homo sapiens	8-hydroxywarfarin binds to UGT2B7 protein	affects^binding	25393417
20	81-81-2	ABCB1	Homo sapiens	ABCB1 polymorphism affects the susceptibility to Warfarin	affects^response to substance	24092646\|25312789
21	81-81-2	ABCC6	Mus musculus	ABCC6 gene mutant form results in increased susceptibility to Warfarin	increases^response to substance	23415960
22	81-81-2	ABCC6	Mus musculus	[Magnesium deficiency co-treated with Phosphates] promotes the reaction [ABCC6 gene mutant form results in increased susceptibility to Warfarin]	affects^cotreatment\|increases^reaction\|increases^response to substance	23415960
23	81-81-2	ABCG2	Homo sapiens	ABCG2 SNP affects the susceptibility to Warfarin	affects^response to substance	25300812
24	81-81-2	ACTA2	Rattus norvegicus	[Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of ACTA2 mRNA	affects^cotreatment\|increases^expression	23117658
25	81-81-2	ACTB	Mus musculus	Warfarin results in decreased expression of ACTB mRNA	decreases^expression	20493250
26	81-81-2	ACTB	Mus musculus	Warfarin results in increased expression of ACTB mRNA	increases^expression	20493250
27	81-81-2	ACTR3	Mus musculus	Warfarin results in increased expression of ACTR3 mRNA	increases^expression	20493250
28	81-81-2	AHCY	Mus musculus	Warfarin results in decreased expression of AHCY mRNA	decreases^expression	20493250
29	81-81-2	AKT1	Rattus norvegicus	6-N,N-diethyl-beta,gamma-dibromomethylene-D-ATP inhibits the reaction [[Warfarin co-treated with Phosphates] results in decreased phosphorylation of AKT1 protein]	affects^cotreatment\|decreases^phosphorylation\|decreases^reaction	22659116
30	81-81-2	AKT1	Rattus norvegicus	Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased phosphorylation of AKT1 protein]	affects^cotreatment\|decreases^phosphorylation\|decreases^reaction	27212383
31	81-81-2	AKT1	Rattus norvegicus	[Warfarin co-treated with Phosphates] results in decreased phosphorylation of AKT1 protein	affects^cotreatment\|decreases^phosphorylation	22659116
32	81-81-2	AKT1	Rattus norvegicus	[Warfarin co-treated with Vitamin K 1] results in decreased phosphorylation of AKT1 protein	affects^cotreatment\|decreases^phosphorylation	27212383
33	81-81-2	ALB	Homo sapiens	Aspirin inhibits the reaction [Warfarin binds to ALB protein]	affects^binding\|decreases^reaction	25499135
34	81-81-2	ALB	Homo sapiens	prodan inhibits the reaction [Warfarin binds to ALB protein]	affects^binding\|decreases^reaction	12044178
35	81-81-2	ALB	Homo sapiens	Pyruvaldehyde inhibits the reaction [Warfarin binds to ALB protein]	affects^binding\|decreases^reaction	20934417
36	81-81-2	ALB	Homo sapiens	Warfarin binds to ALB protein	affects^binding	19596536\|20934417\|20956006\|25499135
37	81-81-2	ALB	Homo sapiens	[Warfarin binds to ALB protein] inhibits the reaction [copper (II) diacetyl-di(N(4)-methylthiosemicarbazone) binds to ALB protein]	affects^binding\|decreases^reaction	18937368
38	81-81-2	ALB	Homo sapiens	[Warfarin binds to ALB protein] inhibits the reaction [copper pyruvaldehyde bis(N(4)-methylthiosemicarbazone) complex binds to ALB protein]	affects^binding\|decreases^reaction	18937368
39	81-81-2	ALB	Rattus norvegicus	Warfarin results in decreased expression of ALB protein	decreases^expression	22342526
40	81-81-2	ALOX5AP	Homo sapiens	Warfarin results in increased expression of ALOX5AP mRNA	increases^expression	16698924
41	81-81-2	ALPL	Mus musculus	Warfarin inhibits the reaction [BMP2 protein results in increased activity of ALPL protein]	decreases^reaction\|increases^activity	21910061
42	81-81-2	ALPL	Mus musculus	Warfarin inhibits the reaction [BMP2 protein results in increased expression of ALPL mRNA]	decreases^reaction\|increases^expression	21910061
43	81-81-2	ALPL	Mus musculus	Warfarin inhibits the reaction [RUNX2 protein results in increased expression of ALPL mRNA]	decreases^reaction\|increases^expression	21910061
44	81-81-2	ANXA4	Mus musculus	Warfarin results in decreased expression of ANXA4 mRNA	decreases^expression	20493250
45	81-81-2	ANXA5	Mus musculus	Warfarin results in decreased expression of ANXA5 mRNA	decreases^expression	20493250
46	81-81-2	APOE	Homo sapiens	APOE gene mutant form affects the susceptibility to Warfarin	affects^response to substance	21228733
47	81-81-2	APOE	Homo sapiens	APOE gene polymorphism affects the susceptibility to Warfarin	affects^response to substance	16847429\|17048007\|17325732
48	81-81-2	APOE	Homo sapiens	APOE polymorphism affects the susceptibility to Warfarin	affects^response to substance	25312789
49	81-81-2	APOE	Homo sapiens	APOE protein affects the susceptibility to Warfarin	affects^response to substance	15952022
50	81-81-2	APOE	Homo sapiens	APOE SNP affects the susceptibility to Warfarin	affects^response to substance	28079798
51	81-81-2	APOE	Mus musculus	APOE gene mutant form results in increased susceptibility to Warfarin	increases^response to substance	23415960
52	81-81-2	ARHGDIA	Mus musculus	Warfarin results in increased expression of ARHGDIA mRNA	increases^expression	20493250
53	81-81-2	ARSE	Gallus gallus	Warfarin results in decreased activity of ARSE protein	decreases^activity	15246527
54	81-81-2	AXIN2	Rattus norvegicus	Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of AXIN2 mRNA]	affects^cotreatment\|decreases^reaction\|increases^expression	23117658
55	81-81-2	AXIN2	Rattus norvegicus	Quercetin inhibits the reaction [Warfarin results in increased expression of AXIN2 mRNA]	decreases^reaction\|increases^expression	23117658
56	81-81-2	AXIN2	Rattus norvegicus	[Warfarin co-treated with Vitamin K] results in increased expression of AXIN2 mRNA	affects^cotreatment\|increases^expression	23117658
57	81-81-2	AXIN2	Rattus norvegicus	Warfarin results in increased expression of AXIN2 mRNA	increases^expression	23117658
58	81-81-2	AXL	Homo sapiens	AXL protein promotes the reaction [Warfarin results in increased susceptibility to gemcitabine]	increases^reaction\|increases^response to substance	26206560
59	81-81-2	AXL	Homo sapiens	AXL protein results in increased susceptibility to Warfarin	increases^response to substance	26206560
60	81-81-2	AXL	Homo sapiens	Vitamin K inhibits the reaction [Warfarin results in decreased expression of AXL protein modified form]	decreases^expression\|decreases^reaction	26206560
61	81-81-2	AXL	Homo sapiens	Warfarin inhibits the reaction [GAS6 protein results in increased activity of AXL protein]	decreases^reaction\|increases^activity	26206560
62	81-81-2	AXL	Homo sapiens	Warfarin results in decreased expression of AXL protein	decreases^expression	26206560
63	81-81-2	AXL	Homo sapiens	Warfarin results in decreased expression of AXL protein modified form	decreases^expression	26206560
64	81-81-2	AXL	Rattus norvegicus	Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased expression of AXL protein]	affects^cotreatment\|decreases^expression\|decreases^reaction	27212383
65	81-81-2	AXL	Rattus norvegicus	[Warfarin co-treated with Vitamin K 1] results in decreased expression of AXL protein	affects^cotreatment\|decreases^expression	27212383
66	81-81-2	BCL2	Rattus norvegicus	Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased expression of BCL2 protein]	affects^cotreatment\|decreases^expression\|decreases^reaction	27212383
67	81-81-2	BCL2	Rattus norvegicus	[Warfarin co-treated with Vitamin K 1] results in decreased expression of BCL2 protein	affects^cotreatment\|decreases^expression	27212383
68	81-81-2	BGLAP	Mus musculus	Warfarin inhibits the reaction [BMP2 protein results in increased activity of BGLAP protein]	decreases^reaction\|increases^activity	21910061
69	81-81-2	BGLAP	Mus musculus	Warfarin inhibits the reaction [BMP2 protein results in increased expression of BGLAP mRNA]	decreases^reaction\|increases^expression	21910061
70	81-81-2	BGLAP	Mus musculus	Warfarin inhibits the reaction [RUNX2 protein results in increased expression of BGLAP mRNA]	decreases^reaction\|increases^expression	21910061
71	81-81-2	BGLAP	Rattus norvegicus	Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of BGLAP mRNA]	affects^cotreatment\|decreases^reaction\|increases^expression	23117658
72	81-81-2	BGLAP	Rattus norvegicus	Quercetin inhibits the reaction [Warfarin results in increased expression of BGLAP mRNA]	decreases^reaction\|increases^expression	23223575
73	81-81-2	BGLAP	Rattus norvegicus	[Warfarin co-treated with Vitamin K] results in increased expression of BGLAP mRNA	affects^cotreatment\|increases^expression	23117658
74	81-81-2	BGLAP	Rattus norvegicus	Warfarin results in increased expression of BGLAP mRNA	increases^expression	23223575
75	81-81-2	BMP2	Mus musculus	Warfarin inhibits the reaction [BMP2 protein results in increased activity of RUNX2 protein]	decreases^reaction\|increases^activity	21910061
76	81-81-2	BMP2	Mus musculus	Warfarin inhibits the reaction [BMP2 protein results in increased expression of COL1A1 mRNA]	decreases^reaction\|increases^expression	21910061
77	81-81-2	BMP2	Mus musculus	Warfarin inhibits the reaction [BMP2 protein results in increased expression of SP7 mRNA]	decreases^reaction\|increases^expression	21910061
78	81-81-2	BMP2	Rattus norvegicus	Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 mRNA]	affects^cotreatment\|affects^expression\|affects^reaction	27412937
79	81-81-2	BMP2	Rattus norvegicus	Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 protein]	affects^cotreatment\|affects^expression\|affects^reaction	27412937
80	81-81-2	BMP2	Rattus norvegicus	[Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 mRNA	affects^cotreatment\|affects^expression	27412937
81	81-81-2	BMP2	Rattus norvegicus	[Warfarin co-treated with Vitamin K 1] affects the expression of BMP2 protein	affects^cotreatment\|affects^expression	27412937
82	81-81-2	C1QBP	Mus musculus	Warfarin results in increased expression of C1QBP mRNA	increases^expression	20493250
83	81-81-2	CALR	Mus musculus	Warfarin results in increased expression of CALR mRNA	increases^expression	20493250
84	81-81-2	CALU	Homo sapiens	CALU polymorphism affects the susceptibility to Warfarin	affects^response to substance	20200517
85	81-81-2	CALU	Rattus norvegicus	CALU protein results in decreased susceptibility to Warfarin	decreases^response to substance	11641264
86	81-81-2	CASP3	Homo sapiens	Warfarin results in increased expression of CASP3 protein modified form	increases^expression	26206560
87	81-81-2	CASP3	Mus musculus	[Warfarin co-treated with Vitamin K 1] results in increased cleavage of CASP3 protein	affects^cotreatment\|increases^cleavage	23990204
88	81-81-2	CASP3	Mus musculus	Warfarin results in decreased expression of CASP3 mRNA	decreases^expression	20493250
89	81-81-2	CASP3	Rattus norvegicus	Warfarin results in increased expression of CASP3 mRNA	increases^expression	19815060
90	81-81-2	CAT	Rattus norvegicus	Warfarin results in increased activity of CAT protein	increases^activity	22342526
91	81-81-2	CCND1	Rattus norvegicus	Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of CCND1 mRNA]	affects^cotreatment\|decreases^reaction\|increases^expression	23117658
92	81-81-2	CCND1	Rattus norvegicus	Quercetin inhibits the reaction [Warfarin results in increased expression of CCND1 mRNA]	decreases^reaction\|increases^expression	23117658
93	81-81-2	CCND1	Rattus norvegicus	[Warfarin co-treated with Vitamin K] results in increased expression of CCND1 mRNA	affects^cotreatment\|increases^expression	23117658
94	81-81-2	CCND1	Rattus norvegicus	Warfarin results in increased expression of CCND1 mRNA	increases^expression	23117658
95	81-81-2	CCT5	Mus musculus	Warfarin results in increased expression of CCT5 mRNA	increases^expression	20493250
96	81-81-2	CCT6A	Mus musculus	Warfarin results in increased expression of CCT6A mRNA	increases^expression	20493250
97	81-81-2	CCT8	Mus musculus	Warfarin results in decreased expression of CCT8 mRNA	decreases^expression	20493250
98	81-81-2	CDC42	Mus musculus	Warfarin results in decreased expression of CDC42 mRNA	decreases^expression	20493250
99	81-81-2	CDH1	Homo sapiens	Warfarin results in increased expression of CDH1 protein	increases^expression	26206560
100	81-81-2	CLIC1	Mus musculus	Warfarin results in decreased expression of CLIC1 mRNA	decreases^expression	20493250
101	81-81-2	CNN1	Rattus norvegicus	[Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of CNN1 mRNA	affects^cotreatment\|increases^expression	23117658
102	81-81-2	COL1A1	Rattus norvegicus	Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of COL1A1 mRNA]	affects^cotreatment\|decreases^reaction\|increases^expression	23117658
103	81-81-2	COL1A1	Rattus norvegicus	Quercetin inhibits the reaction [Warfarin results in increased expression of COL1A1 mRNA]	decreases^reaction\|increases^expression	23223575
104	81-81-2	COL1A1	Rattus norvegicus	[Warfarin co-treated with Vitamin K] results in increased expression of COL1A1 mRNA	affects^cotreatment\|increases^expression	23117658
105	81-81-2	COL1A1	Rattus norvegicus	Warfarin results in increased expression of COL1A1 mRNA	increases^expression	23223575
106	81-81-2	COX5A	Mus musculus	Warfarin results in increased expression of COX5A mRNA	increases^expression	20493250
107	81-81-2	CRK	Mus musculus	Warfarin results in increased expression of CRK mRNA	increases^expression	20493250
108	81-81-2	CTNNB1	Homo sapiens	Warfarin results in decreased expression of and affects the localization of CTNNB1 protein	affects^localization\|decreases^expression	26206560
109	81-81-2	CTNNB1	Rattus norvegicus	CTNNB1 protein affects the susceptibility to Warfarin	affects^response to substance	23223575
110	81-81-2	CTNNB1	Rattus norvegicus	Quercetin inhibits the reaction [Warfarin results in increased expression of and affects the localization of CTNNB1 protein]	affects^localization\|decreases^reaction\|increases^expression	23117658
111	81-81-2	CTNNB1	Rattus norvegicus	Warfarin results in increased expression of and affects the localization of CTNNB1 protein	affects^localization\|increases^expression	23117658
112	81-81-2	CXCL8		Warfarin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of CXCL8 mRNA]	decreases^reaction\|increases^expression	24603311
113	81-81-2	CYP1A1	Mus musculus	Warfarin results in decreased activity of CYP1A1 protein	decreases^activity	18420780
114	81-81-2	CYP1A2	Homo sapiens	CYP1A2 SNP affects the susceptibility to Warfarin	affects^response to substance	28079798
115	81-81-2	CYP2A4	Mus musculus	Warfarin results in decreased activity of CYP2A4 protein	decreases^activity	18420780
116	81-81-2	CYP2B10	Mus musculus	Warfarin results in decreased activity of CYP2B10 protein	decreases^activity	18420780
117	81-81-2	CYP2C18	Homo sapiens	CYP2C18 gene polymorphism affects the susceptibility to Warfarin	affects^response to substance	19752777
118	81-81-2	CYP2C18	Homo sapiens	CYP2C18 protein affects the susceptibility to Warfarin	affects^response to substance	19752777
119	81-81-2	CYP2C19	Homo sapiens	CYP2C19 gene polymorphism affects the metabolism of and affects the susceptibility to Warfarin	affects^metabolic processing\|affects^response to substance	25652102
120	81-81-2	CYP2C19	Homo sapiens	CYP2C19 gene polymorphism affects the susceptibility to Warfarin	affects^response to substance	19752777
121	81-81-2	CYP2C19	Homo sapiens	CYP2C19 polymorphism affects the susceptibility to Warfarin	affects^response to substance	27356304
122	81-81-2	CYP2C19	Homo sapiens	CYP2C19 protein affects the susceptibility to Warfarin	affects^response to substance	19752777
123	81-81-2	CYP2C19	Macaca fascicularis	CYP2C19 protein polymorphism affects the susceptibility to Warfarin	affects^response to substance	25036290
124	81-81-2	CYP2C29	Mus musculus	Warfarin results in decreased activity of CYP2C29 protein	decreases^activity	18420780
125	81-81-2	CYP2C9	Homo sapiens	CYP2C9 affects the susceptibility to Warfarin	affects^response to substance	22907842
126	81-81-2	CYP2C9	Homo sapiens	CYP2C9 gene affects the susceptibility to Warfarin	affects^response to substance	11127854\|11307788\|14676821\|15001971\|15284536\|15371982\|19207028
127	81-81-2	CYP2C9	Homo sapiens	CYP2C9 gene mutant form affects the susceptibility to Warfarin	affects^response to substance	20354686\|21261182\|21428138
128	81-81-2	CYP2C9	Homo sapiens	CYP2C9 gene mutant form results in increased susceptibility to Warfarin	increases^response to substance	25994031\|26255664
129	81-81-2	CYP2C9	Homo sapiens	CYP2C9 gene polymorphism affects the susceptibility to and affects the metabolism of Warfarin	affects^metabolic processing\|affects^response to substance	26469104
130	81-81-2	CYP2C9	Homo sapiens	CYP2C9 gene polymorphism affects the susceptibility to Warfarin	affects^response to substance	14656880\|14691573\|15050794\|15100169\|15900281\|15900282\|15940194\|16432637\|16611750\|16676068\|16708125\|16847429\|16878445\|16890578\|16960144\|17048007\|17049586\|17111199\|17387222\|17456829\|17496169\|17672075\|17764537\|18370846\|18429757\|18535201\|18542936\|18574025\|18698879\|18756910\|18776969\|18836275\|19300499\|19567378\|19745563\|19998810\|20386359\|20615525\|20677151\|20842355\|21110192\|21228733\|21590310\|21681008\|22198820\|22528326\|23376925\|24474498\|25298588\|25521356\|25652102\|25699611\|25747538\|25866574\|25904339\|26418980\|26502504\|27581200
131	81-81-2	CYP2C9	Homo sapiens	CYP2C9 gene polymorphism results in decreased susceptibility to Warfarin	decreases^response to substance	18030307\|18034619
132	81-81-2	CYP2C9	Homo sapiens	CYP2C9 gene polymorphism results in increased susceptibility to Warfarin	increases^response to substance	11794436\|19899329
133	81-81-2	CYP2C9	Homo sapiens	CYP2C9 gene SNP affects the susceptibility to Warfarin	affects^response to substance	20442691\|20653674\|20833655\|20854800\|21270790\|21320153\|21321468\|21326313\|21451434\|21562147\|21635147\|21639946\|22266406\|26223945\|26568290
134	81-81-2	CYP2C9	Homo sapiens	CYP2C9 polymorphism affects the susceptibility to Warfarin	affects^response to substance	17510308\|17895500\|17955230\|18570163\|20072124\|20339978\|20637959\|20884456\|21713378\|21786578\|21911247\|22040439\|22161100\|22248286\|22274142\|22533669\|22594507\|22855348\|23061746\|23159229\|23167228\|23183958\|23208322\|23276529\|23279643\|23602689\|23688605\|23710884\|23990957\|24956244\|24978953\|25042728\|25312789\|26940072\|27055637
135	81-81-2	CYP2C9	Homo sapiens	CYP2C9 protein affects the susceptibility to Warfarin	affects^response to substance	15952022\|17456829\|18034618\|19745563\|19752777\|20375999\|22990331\|24750390
136	81-81-2	CYP2C9	Homo sapiens	CYP2C9 protein polymorphism affects the susceptibility to Warfarin	affects^response to substance	23800980\|24601977\|25075423
137	81-81-2	CYP2C9	Homo sapiens	CYP2C9 protein results in increased susceptibility to Warfarin	increases^response to substance	17049586\|17111199\|17387222\|17496169\|18542936
138	81-81-2	CYP2C9	Homo sapiens	CYP2C9 results in increased susceptibility to Warfarin	increases^response to substance	20420818
139	81-81-2	CYP2C9	Homo sapiens	CYP2C9 SNP affects the susceptibility to Warfarin	affects^response to substance	24966969\|28079798
140	81-81-2	CYP2C9	Homo sapiens	CYP2C9 SNP affects the susceptibility to Warfarin analog	affects^response to substance	25499099
141	81-81-2	CYP2C9	Homo sapiens	Simvastatin affects the reaction [CYP2C9 polymorphism affects the susceptibility to Warfarin]	affects^reaction\|affects^response to substance	22594507
142	81-81-2	CYP2C9	Homo sapiens	[Warfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP2C9 mRNA	affects^binding\|increases^activity\|increases^expression	20735727
143	81-81-2	CYP2C9	Homo sapiens	Warfarin results in decreased activity of CYP2C9 protein	decreases^activity	18420780
144	81-81-2	CYP2D6	Homo sapiens	Warfarin results in decreased activity of CYP2D6 protein	decreases^activity	18420780
145	81-81-2	CYP3A2	Rattus norvegicus	CYP3A2 mRNA affects the susceptibility to Warfarin	affects^response to substance	11531004
146	81-81-2	CYP3A2	Rattus norvegicus	Warfarin results in increased expression of CYP3A2 mRNA	increases^expression	11531004
147	81-81-2	CYP3A4	Homo sapiens	CYP3A4 SNP affects the susceptibility to Warfarin	affects^response to substance	28079798
148	81-81-2	CYP3A4	Homo sapiens	[Warfarin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA	affects^binding\|increases^activity\|increases^expression	20735727
149	81-81-2	CYP3A4	Homo sapiens	Warfarin results in decreased activity of CYP3A4 protein	decreases^activity	18420780
150	81-81-2	CYP3A5	Homo sapiens	CYP3A5 gene polymorphism affects the susceptibility to Warfarin	affects^response to substance	19752777
151	81-81-2	CYP3A5	Homo sapiens	CYP3A5 protein affects the susceptibility to Warfarin	affects^response to substance	19752777
152	81-81-2	CYP3A65	Danio rerio	Warfarin results in increased expression of CYP3A65 mRNA	increases^expression	25094061
153	81-81-2	CYP4F2	Homo sapiens	CYP4F2 gene affects the susceptibility to Warfarin	affects^response to substance	19207028
154	81-81-2	CYP4F2	Homo sapiens	CYP4F2 gene mutant form affects the susceptibility to Warfarin	affects^response to substance	20553802
155	81-81-2	CYP4F2	Homo sapiens	CYP4F2 gene polymorphism affects the susceptibility to Warfarin	affects^response to substance	18250228\|19270263\|19300499\|20217574\|22172097\|22192158\|22198820\|22528326\|22892446\|26418980
156	81-81-2	CYP4F2	Homo sapiens	[CYP4F2 gene polymorphism co-treated with VKORC1 gene mutant form] affects the susceptibility to Warfarin	affects^cotreatment\|affects^response to substance	21084764
157	81-81-2	CYP4F2	Homo sapiens	CYP4F2 gene SNP affects the susceptibility to Warfarin	affects^response to substance	20442691\|20833655\|21326313\|21562147\|25747538\|26223945
158	81-81-2	CYP4F2	Homo sapiens	CYP4F2 polymorphism affects the susceptibility to Warfarin	affects^response to substance	20653676\|23061746\|25042728
159	81-81-2	CYP4F2	Homo sapiens	CYP4F2 protein polymorphism affects the susceptibility to Warfarin	affects^response to substance	23215885
160	81-81-2	CYP4F2	Homo sapiens	CYP4F2 protein results in increased susceptibility to Warfarin	increases^response to substance	18250228
161	81-81-2	CYP4F2	Homo sapiens	CYP4F2 SNP affects the susceptibility to Warfarin	affects^response to substance	28079798
162	81-81-2	DCTN2	Mus musculus	Warfarin results in decreased expression of DCTN2 mRNA	decreases^expression	20493250
163	81-81-2	DDT	Mus musculus	Warfarin results in decreased expression of DDT mRNA	decreases^expression	20493250
164	81-81-2	DLST	Mus musculus	Warfarin results in decreased expression of DLST mRNA	decreases^expression	20493250
165	81-81-2	DOCK7	Mus musculus	Warfarin results in increased expression of DOCK7 mRNA	increases^expression	20493250
166	81-81-2	DPYSL2	Mus musculus	Warfarin results in increased expression of DPYSL2 mRNA	increases^expression	20493250
167	81-81-2	DSTN	Mus musculus	Warfarin results in decreased expression of DSTN mRNA	decreases^expression	20493250
168	81-81-2	EEF2	Mus musculus	Warfarin results in decreased expression of EEF2 mRNA	decreases^expression	20493250
169	81-81-2	EIF3I	Mus musculus	Warfarin results in decreased expression of EIF3I mRNA	decreases^expression	20493250
170	81-81-2	EMCN	Homo sapiens	Warfarin results in decreased expression of EMCN protein	decreases^expression	26206560
171	81-81-2	ENPP1	Rattus norvegicus	Warfarin results in increased expression of ENPP1 mRNA	increases^expression	22659116
172	81-81-2	ENPP1	Rattus norvegicus	Warfarin results in increased expression of ENPP1 protein	increases^expression	22659116
173	81-81-2	EPHX1	Homo sapiens	EPHX1 gene polymorphism affects the susceptibility to Warfarin	affects^response to substance	17496169\|20842355
174	81-81-2	EPHX1	Homo sapiens	EPHX1 gene SNP affects the susceptibility to Warfarin	affects^response to substance	15900282\|25629049
175	81-81-2	EPHX1	Homo sapiens	EPHX1 intron SNP affects the susceptibility to Warfarin	affects^response to substance	21192345
176	81-81-2	EPHX1	Homo sapiens	EPHX1 polymorphism affects the susceptibility to Warfarin	affects^response to substance	24092646
177	81-81-2	EPHX1	Homo sapiens	EPHX1 protein results in increased susceptibility to Warfarin	increases^response to substance	17496169
178	81-81-2	EPHX1	Homo sapiens	EPHX1 SNP affects the susceptibility to Warfarin	affects^response to substance	28079798
179	81-81-2	ERP29	Mus musculus	Warfarin results in decreased expression of ERP29 mRNA	decreases^expression	20493250
180	81-81-2	F10	Rattus norvegicus	Warfarin results in decreased activity of F10 protein	decreases^activity	20371969
181	81-81-2	F2	Homo sapiens	F2 gene polymorphism affects the susceptibility to Warfarin	affects^response to substance	14656880
182	81-81-2	F2	Homo sapiens	Fenofibrate promotes the reaction [Warfarin results in decreased expression of F2 protein]	decreases^expression\|increases^reaction	9681093
183	81-81-2	F2	Homo sapiens	Warfarin results in decreased expression of F2 protein	decreases^expression	9681093
184	81-81-2	F5	Homo sapiens	F5 gene polymorphism affects the susceptibility to Warfarin	affects^response to substance	19752777
185	81-81-2	F5	Homo sapiens	F5 protein affects the susceptibility to Warfarin	affects^response to substance	19752777
186	81-81-2	F7	Homo sapiens	F7 gene mutant form affects the susceptibility to Warfarin	affects^response to substance	20885134
187	81-81-2	F7	Homo sapiens	F7 gene polymorphism affects the susceptibility to Warfarin	affects^response to substance	14656880
188	81-81-2	F7	Homo sapiens	Fenofibrate promotes the reaction [Warfarin results in decreased expression of F7 protein]	decreases^expression\|increases^reaction	9681093
189	81-81-2	F7	Homo sapiens	Warfarin results in decreased expression of F7 protein	decreases^expression	9681093
190	81-81-2	F7	Rattus norvegicus	Warfarin results in decreased activity of F7 protein	decreases^activity	20371969
191	81-81-2	FPGS	Homo sapiens	FPGS gene polymorphism affects the susceptibility to Warfarin	affects^response to substance	25079360
192	81-81-2	FSCN1	Mus musculus	Warfarin results in decreased expression of FSCN1 mRNA	decreases^expression	20493250
193	81-81-2	G3BP1	Mus musculus	Warfarin results in increased expression of G3BP1 mRNA	increases^expression	20493250
194	81-81-2	GALE	Mus musculus	Warfarin results in decreased expression of GALE mRNA	decreases^expression	20493250
195	81-81-2	GAS6	Rattus norvegicus	Vitamin K 2 inhibits the reaction [[Warfarin co-treated with Vitamin K 1] results in decreased expression of GAS6 protein]	affects^cotreatment\|decreases^expression\|decreases^reaction	27212383
196	81-81-2	GAS6	Rattus norvegicus	[Warfarin co-treated with Vitamin K 1] results in decreased expression of GAS6 protein	affects^cotreatment\|decreases^expression	27212383
197	81-81-2	GAS6	Rattus norvegicus	Warfarin results in decreased expression of GAS6 protein	decreases^expression	19564549
198	81-81-2	GDI2	Mus musculus	Warfarin results in increased expression of GDI2 mRNA	increases^expression	20493250
199	81-81-2	GGCX	Danio rerio	Warfarin results in increased expression of GGCX mRNA	increases^expression	25094061
200	81-81-2	GGCX	Homo sapiens	GGCX gene polymorphism affects the susceptibility to Warfarin	affects^response to substance	17049586\|17496169\|17764537
201	81-81-2	GGCX	Homo sapiens	GGCX gene polymorphism results in decreased susceptibility to Warfarin	decreases^response to substance	16676068
202	81-81-2	GGCX	Homo sapiens	GGCX gene SNP affects the susceptibility to Warfarin	affects^response to substance	21195460\|21326313
203	81-81-2	GGCX	Homo sapiens	GGCX polymorphism affects the susceptibility to Warfarin	affects^response to substance	22161100\|25042728
204	81-81-2	GGCX	Homo sapiens	GGCX protein results in increased susceptibility to Warfarin	increases^response to substance	17049586\|17496169
205	81-81-2	GMPS	Mus musculus	Warfarin results in increased expression of GMPS mRNA	increases^expression	20493250
206	81-81-2	GSK3B	Rattus norvegicus	Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased phosphorylation of GSK3B protein]	affects^cotreatment\|decreases^reaction\|increases^phosphorylation	23117658
207	81-81-2	GSK3B	Rattus norvegicus	[Warfarin co-treated with Vitamin K] results in increased phosphorylation of GSK3B protein	affects^cotreatment\|increases^phosphorylation	23117658
208	81-81-2	HDAC1	Mus musculus	Warfarin results in increased expression of HDAC1 mRNA	increases^expression	20493250
209	81-81-2	HINT1	Mus musculus	Warfarin results in increased expression of HINT1 mRNA	increases^expression	20493250
210	81-81-2	HMOX1	Rattus norvegicus	Warfarin affects the expression of HMOX1 mRNA	affects^expression	22954530
211	81-81-2	HNRNPAB	Mus musculus	Warfarin results in increased expression of HNRNPAB mRNA	increases^expression	20493250
212	81-81-2	HNRNPDL	Mus musculus	Warfarin results in decreased expression of HNRNPDL mRNA	decreases^expression	20493250
213	81-81-2	HNRNPF	Mus musculus	Warfarin results in increased expression of HNRNPF mRNA	increases^expression	20493250
214	81-81-2	HNRNPK	Mus musculus	Warfarin results in decreased expression of HNRNPK mRNA	decreases^expression	20493250
215	81-81-2	HNRNPK	Mus musculus	Warfarin results in increased expression of HNRNPK mRNA	increases^expression	20493250
216	81-81-2	HP	Rattus norvegicus	Warfarin results in increased expression of HP protein	increases^expression	22342526
217	81-81-2	HSP90AB1	Mus musculus	Warfarin results in decreased expression of HSP90AB1 mRNA	decreases^expression	20493250
218	81-81-2	HSPA8	Mus musculus	Warfarin results in increased expression of HSPA8 mRNA	increases^expression	20493250
219	81-81-2	HSPD1	Mus musculus	Warfarin results in increased expression of HSPD1 mRNA	increases^expression	20493250
220	81-81-2	IFNG		Warfarin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of IFNG mRNA]	increases^expression\|increases^reaction	24603311
221	81-81-2	IL12A	Rattus norvegicus	Warfarin results in increased expression of IL12A mRNA	increases^expression	22342526
222	81-81-2	IL12B	Rattus norvegicus	Warfarin results in increased expression of IL12B mRNA	increases^expression	22342526
223	81-81-2	IL1B	Homo sapiens	Warfarin inhibits the reaction [Vitamin K 2 results in decreased susceptibility to IL1B protein]	decreases^reaction\|decreases^response to substance	20460758
224	81-81-2	IL1B	Rattus norvegicus	[Warfarin co-treated with Vitamin K] results in increased expression of IL1B mRNA	affects^cotreatment\|increases^expression	23117658
225	81-81-2	IL1B		Warfarin inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased expression of IL1B mRNA]	decreases^reaction\|increases^expression	24603311
226	81-81-2	IL2		Warfarin promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL2 mRNA]	increases^expression\|increases^reaction	24603311
227	81-81-2	IL6	Mus musculus	Warfarin results in decreased expression of IL6 protein	decreases^expression	18772604
228	81-81-2	IL6	Rattus norvegicus	[Warfarin co-treated with Vitamin K] results in increased expression of IL6 mRNA	affects^cotreatment\|increases^expression	23117658
229	81-81-2	IL6	Rattus norvegicus	Warfarin results in decreased expression of IL6 mRNA	decreases^expression	26742017
230	81-81-2	IL6	Rattus norvegicus	Warfarin results in increased expression of IL6 protein	increases^expression	22342526
231	81-81-2	IPO5	Mus musculus	Warfarin results in decreased expression of IPO5 mRNA	decreases^expression	20493250
232	81-81-2	ISYNA1	Mus musculus	Warfarin results in increased expression of ISYNA1 mRNA	increases^expression	20493250
233	81-81-2	KRT18	Mus musculus	Warfarin results in decreased expression of KRT18 mRNA	decreases^expression	20493250
234	81-81-2	LASP1	Mus musculus	Warfarin results in decreased expression of LASP1 mRNA	decreases^expression	20493250
235	81-81-2	MGP	Danio rerio	Warfarin results in increased expression of MGP mRNA	increases^expression	25094061
236	81-81-2	MGP	Mus musculus	[Warfarin co-treated with Vitamin K 1] results in decreased activity of MGP protein	affects^cotreatment\|decreases^activity	23990204
237	81-81-2	MGP	Mus musculus	[Warfarin co-treated with Vitamin K 1] results in decreased carboxylation of MGP protein	affects^cotreatment\|decreases^carboxylation	23990204
238	81-81-2	MGP	Mus musculus	[[Warfarin co-treated with Vitamin K 1] results in decreased carboxylation of MGP protein] which results in decreased activity of MGP protein	affects^cotreatment\|decreases^activity\|decreases^carboxylation	23990204
239	81-81-2	MGP	Mus musculus	[Warfarin co-treated with Vitamin K 1] results in decreased expression of MGP mRNA	affects^cotreatment\|decreases^expression	23990204
240	81-81-2	MGP	Rattus norvegicus	[Quercetin co-treated with Warfarin] results in decreased carboxylation of MGP protein	affects^cotreatment\|decreases^carboxylation	23223575
241	81-81-2	MGP	Rattus norvegicus	[Vitamin K co-treated with Warfarin] results in increased carboxylation of MGP protein	affects^cotreatment\|increases^carboxylation	23223575
242	81-81-2	MGP	Rattus norvegicus	Warfarin inhibits the reaction [Vitamin K 1 results in increased expression of and results in increased secretion of MGP protein modified form]	decreases^reaction\|increases^expression\|increases^secretion	21705322
243	81-81-2	MGP	Rattus norvegicus	Warfarin results in decreased expression of and results in decreased secretion of MGP protein	decreases^expression\|decreases^secretion	21705322
244	81-81-2	MGP	Rattus norvegicus	Warfarin results in decreased expression of and results in decreased secretion of MGP protein modified form	decreases^expression\|decreases^secretion	21705322
245	81-81-2	MIR133A2	Homo sapiens	MIR133A2 gene SNP affects the susceptibility to Warfarin	affects^response to substance	26113018
246	81-81-2	MPO	Rattus norvegicus	Warfarin results in increased activity of MPO protein	increases^activity	26742017
247	81-81-2	MYH1	Rattus norvegicus	[Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of MYH1 mRNA	affects^cotreatment\|increases^expression	23117658
248	81-81-2	NMRAL1	Mus musculus	Warfarin results in increased expression of NMRAL1 mRNA	increases^expression	20493250
249	81-81-2	NQO1	Homo sapiens	NQO1 gene SNP affects the susceptibility to Warfarin	affects^response to substance	26257249\|27581200
250	81-81-2	NQO1	Homo sapiens	NQO1 polymorphism affects the susceptibility to Warfarin	affects^response to substance	23215885
251	81-81-2	NR1I2	Danio rerio	Warfarin results in increased expression of NR1I2 mRNA	increases^expression	25094061
252	81-81-2	NR1I2	Homo sapiens	Warfarin binds to and results in increased activity of NR1I2 protein	affects^binding\|increases^activity	20735727
253	81-81-2	NUCB1	Mus musculus	Warfarin results in increased expression of NUCB1 mRNA	increases^expression	20493250
254	81-81-2	NUMB	Rattus norvegicus	Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of NUMB mRNA]	affects^cotreatment\|decreases^reaction\|increases^expression	23117658
255	81-81-2	NUMB	Rattus norvegicus	[Warfarin co-treated with Vitamin K] results in increased expression of NUMB mRNA	affects^cotreatment\|increases^expression	23117658
256	81-81-2	OAT	Mus musculus	Warfarin results in decreased expression of OAT mRNA	decreases^expression	20493250
257	81-81-2	ORM1	Homo sapiens	Chlorpromazine inhibits the reaction [Warfarin binds to ORM1 protein alternative form]	affects^binding\|decreases^reaction	8946472
258	81-81-2	ORM1	Homo sapiens	Dipyridamole inhibits the reaction [Warfarin binds to ORM1 protein alternative form]	affects^binding\|decreases^reaction	8946472
259	81-81-2	ORM1	Homo sapiens	Lidocaine inhibits the reaction [Warfarin binds to ORM1 protein alternative form]	affects^binding\|decreases^reaction	8946472
260	81-81-2	ORM1	Homo sapiens	ORM1 gene polymorphism affects the susceptibility to Warfarin	affects^response to substance	17496169
261	81-81-2	ORM1	Homo sapiens	ORM1 polymorphism affects the susceptibility to Warfarin	affects^response to substance	23208322
262	81-81-2	ORM1	Homo sapiens	ORM1 protein results in increased susceptibility to Warfarin	increases^response to substance	17496169
263	81-81-2	ORM1	Homo sapiens	Progesterone inhibits the reaction [Warfarin binds to ORM1 protein alternative form]	affects^binding\|decreases^reaction	8946472
264	81-81-2	ORM1	Homo sapiens	Warfarin binds to ORM1 protein alternative form	affects^binding	8946472
265	81-81-2	PA2G4	Mus musculus	Warfarin results in increased expression of PA2G4 mRNA	increases^expression	20493250
266	81-81-2	PARP1	Homo sapiens	Warfarin results in increased expression of PARP1 protein modified form	increases^expression	26206560
267	81-81-2	PDGFB	Rattus norvegicus	Warfarin results in decreased expression of PDGFB mRNA	decreases^expression	11290560
268	81-81-2	PDGFB	Rattus norvegicus	Warfarin results in decreased expression of PDGFB protein	decreases^expression	11290560
269	81-81-2	PDIA3	Mus musculus	Warfarin results in decreased expression of PDIA3 mRNA	decreases^expression	20493250
270	81-81-2	PDIA3	Mus musculus	Warfarin results in increased expression of PDIA3 mRNA	increases^expression	20493250
271	81-81-2	PDIA4	Mus musculus	Warfarin results in decreased expression of PDIA4 mRNA	decreases^expression	20493250
272	81-81-2	PGAM1	Mus musculus	Warfarin results in decreased expression of PGAM1 mRNA	decreases^expression	20493250
273	81-81-2	PGAM1	Mus musculus	Warfarin results in increased expression of PGAM1 mRNA	increases^expression	20493250
274	81-81-2	PKM	Mus musculus	Warfarin results in decreased expression of PKM mRNA	decreases^expression	20493250
275	81-81-2	POR	Homo sapiens	POR gene SNP affects the susceptibility to Warfarin	affects^response to substance	27488389
276	81-81-2	PPP1CA	Mus musculus	Warfarin results in decreased expression of PPP1CA mRNA	decreases^expression	20493250
277	81-81-2	PPP2R1A	Mus musculus	Warfarin results in increased expression of PPP2R1A mRNA	increases^expression	20493250
278	81-81-2	PROC	Homo sapiens	PROC gene polymorphism affects the susceptibility to Warfarin	affects^response to substance	17048007\|17496169
279	81-81-2	PROC	Homo sapiens	PROC protein results in increased susceptibility to Warfarin	increases^response to substance	17496169
280	81-81-2	PROS1	Homo sapiens	PROS1 gene polymorphism affects the susceptibility to Warfarin	affects^response to substance	19752777
281	81-81-2	PROS1	Homo sapiens	PROS1 protein affects the susceptibility to Warfarin	affects^response to substance	19752777
282	81-81-2	PROS1	Rodentia	PROS1 protein results in decreased susceptibility to Warfarin	decreases^response to substance	22290807
283	81-81-2	PRSS53	Homo sapiens	PRSS53 gene SNP affects the susceptibility to Warfarin	affects^response to substance	21590310
284	81-81-2	PSMA3	Mus musculus	Warfarin results in decreased expression of PSMA3 mRNA	decreases^expression	20493250
285	81-81-2	PSMA6	Mus musculus	Warfarin results in decreased expression of PSMA6 mRNA	decreases^expression	20493250
286	81-81-2	PSMC2	Mus musculus	Warfarin results in decreased expression of PSMC2 mRNA	decreases^expression	20493250
287	81-81-2	PTH	Mus musculus	Warfarin results in decreased activity of PTH protein	decreases^activity	11564701
288	81-81-2	RAB1A	Mus musculus	Warfarin results in decreased expression of RAB1A mRNA	decreases^expression	20493250
289	81-81-2	RHOA	Mus musculus	Warfarin results in decreased expression of RHOA mRNA	decreases^expression	20493250
290	81-81-2	RPL27	Mus musculus	Warfarin results in increased expression of RPL27 mRNA	increases^expression	20493250
291	81-81-2	RPL9	Mus musculus	Warfarin results in increased expression of RPL9 mRNA	increases^expression	20493250
292	81-81-2	RPLP0	Mus musculus	Warfarin results in increased expression of RPLP0 mRNA	increases^expression	20493250
293	81-81-2	RPSA	Mus musculus	Warfarin results in increased expression of RPSA mRNA	increases^expression	20493250
294	81-81-2	RUNX1	Rattus norvegicus	Quercetin inhibits the reaction [Warfarin results in increased expression of RUNX1 mRNA]	decreases^reaction\|increases^expression	23223575
295	81-81-2	RUNX1	Rattus norvegicus	Warfarin results in increased expression of RUNX1 mRNA	increases^expression	23223575
296	81-81-2	RUNX2	Rattus norvegicus	Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 mRNA]	affects^cotreatment\|affects^expression\|affects^reaction	27412937
297	81-81-2	RUNX2	Rattus norvegicus	Losartan affects the reaction [[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 protein]	affects^cotreatment\|affects^expression\|affects^reaction	27412937
298	81-81-2	RUNX2	Rattus norvegicus	Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of RUNX2 mRNA]	affects^cotreatment\|decreases^reaction\|increases^expression	23117658
299	81-81-2	RUNX2	Rattus norvegicus	[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 mRNA	affects^cotreatment\|affects^expression	27412937
300	81-81-2	RUNX2	Rattus norvegicus	[Warfarin co-treated with Vitamin K 1] affects the expression of RUNX2 protein	affects^cotreatment\|affects^expression	27412937
301	81-81-2	RUNX2	Rattus norvegicus	[Warfarin co-treated with Vitamin K] results in increased expression of RUNX2 mRNA	affects^cotreatment\|increases^expression	23117658
302	81-81-2	RUVBL2	Mus musculus	Warfarin results in decreased expression of RUVBL2 mRNA	decreases^expression	20493250
303	81-81-2	SAE1	Mus musculus	Warfarin results in decreased expression of SAE1 mRNA	decreases^expression	20493250
304	81-81-2	SEPHS1	Mus musculus	Warfarin results in increased expression of SEPHS1 mRNA	increases^expression	20493250
305	81-81-2	SERPINC1	Homo sapiens	Warfarin results in increased expression of SERPINC1 protein	increases^expression	73932
306	81-81-2	SPP1	Mus musculus	[Warfarin co-treated with Vitamin K 1] results in increased expression of SPP1 mRNA	affects^cotreatment\|increases^expression	23990204
307	81-81-2	SPP1	Rattus norvegicus	[Quercetin co-treated with Warfarin] results in increased expression of SPP1 mRNA	affects^cotreatment\|increases^expression	23223575
308	81-81-2	SPP1	Rattus norvegicus	[Warfarin co-treated with Vitamin K] results in increased expression of SPP1 mRNA	affects^cotreatment\|increases^expression	23117658
309	81-81-2	STIP1	Mus musculus	Warfarin results in decreased expression of STIP1 mRNA	decreases^expression	20493250
310	81-81-2	TAGLN	Mus musculus	[Warfarin co-treated with Vitamin K 1] results in decreased expression of TAGLN mRNA	affects^cotreatment\|decreases^expression	23990204
311	81-81-2	TAGLN	Rattus norvegicus	[Warfarin co-treated with Vitamin K co-treated with Quercetin] results in increased expression of TAGLN mRNA	affects^cotreatment\|increases^expression	23117658
312	81-81-2	TCF4	Rattus norvegicus	Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of TCF4 mRNA]	affects^cotreatment\|decreases^reaction\|increases^expression	23117658
313	81-81-2	TCF4	Rattus norvegicus	Quercetin inhibits the reaction [Warfarin results in increased expression of TCF4 mRNA]	decreases^reaction\|increases^expression	23117658
314	81-81-2	TCF4	Rattus norvegicus	[Warfarin co-treated with Vitamin K] results in increased expression of TCF4 mRNA	affects^cotreatment\|increases^expression	23117658
315	81-81-2	TCF4	Rattus norvegicus	Warfarin results in increased expression of TCF4 mRNA	increases^expression	23117658
316	81-81-2	TCP1	Mus musculus	Warfarin results in increased expression of TCP1 mRNA	increases^expression	20493250
317	81-81-2	TGM2	Mus musculus	TGM2 protein affects the susceptibility to Warfarin	affects^response to substance	23117658
318	81-81-2	TGM2	Mus musculus	[TGM2 protein affects the susceptibility to Warfarin] which affects the susceptibility to Quercetin	affects^response to substance	23117658
319	81-81-2	TGM2	Mus musculus	TGM2 protein results in increased susceptibility to Warfarin	increases^response to substance	23117658
320	81-81-2	TGM2	Rattus norvegicus	Quercetin inhibits the reaction [[Warfarin co-treated with Vitamin K] results in increased expression of and results in increased activity of TGM2 protein]	affects^cotreatment\|decreases^reaction\|increases^activity\|increases^expression	23117658
321	81-81-2	TGM2	Rattus norvegicus	Quercetin inhibits the reaction [Warfarin results in increased activity of TGM2 protein]	decreases^reaction\|increases^activity	23117658
322	81-81-2	TGM2	Rattus norvegicus	[Warfarin co-treated with Vitamin K] results in increased expression of and results in increased activity of TGM2 protein	affects^cotreatment\|increases^activity\|increases^expression	23117658
323	81-81-2	TGM2	Rattus norvegicus	Warfarin results in increased expression of and results in increased activity of TGM2 protein	increases^activity\|increases^expression	23117658
324	81-81-2	THOP1	Mus musculus	Warfarin results in increased expression of THOP1 mRNA	increases^expression	20493250
325	81-81-2	TNF	Rattus norvegicus	[Warfarin co-treated with Vitamin K] results in increased expression of TNF mRNA	affects^cotreatment\|increases^expression	23117658
326	81-81-2	TNF	Rattus norvegicus	Warfarin results in decreased expression of TNF mRNA	decreases^expression	22342526\|26742017
327	81-81-2	TNF	Rattus norvegicus	Warfarin results in increased expression of TNF	increases^expression	21565690
328	81-81-2	TP53	Oryctolagus cuniculus	Warfarin affects the expression of TP53 protein	affects^expression	12872399
329	81-81-2	TSKU	Danio rerio	Warfarin results in increased expression of TSKU mRNA	increases^expression	25094061
330	81-81-2	TUBA1A	Mus musculus	Warfarin results in increased expression of TUBA1A mRNA	increases^expression	20493250
331	81-81-2	TUBA1B	Mus musculus	Warfarin results in decreased expression of TUBA1B mRNA	decreases^expression	20493250
332	81-81-2	TUBA1B	Mus musculus	Warfarin results in increased expression of TUBA1B mRNA	increases^expression	20493250
333	81-81-2	TUBB5	Mus musculus	Warfarin results in decreased expression of TUBB5 mRNA	decreases^expression	20493250
334	81-81-2	TUFM	Mus musculus	Warfarin results in decreased expression of TUFM mRNA	decreases^expression	20493250
335	81-81-2	TYRO3	Mus musculus	Warfarin results in decreased expression of TYRO3 mRNA	decreases^expression	18772604
336	81-81-2	U2AF2	Mus musculus	Warfarin results in increased expression of U2AF2 mRNA	increases^expression	20493250
337	81-81-2	UGT1A1	Homo sapiens	UGT1A1 gene SNP affects the susceptibility to Warfarin	affects^response to substance	26223945
338	81-81-2	UGT1A1	Homo sapiens	UGT1A1 polymorphism affects the susceptibility to Warfarin	affects^response to substance	25312789
339	81-81-2	UGT1A1	Homo sapiens	Warfarin binds to and results in decreased activity of UGT1A1 protein	affects^binding\|decreases^activity	25393417
340	81-81-2	UGT1A1	Homo sapiens	[Warfarin binds to and results in decreased activity of UGT1A1 protein] which results in decreased glucuronidation of Estradiol	affects^binding\|decreases^activity\|decreases^glucuronidation	25393417
341	81-81-2	UGT1A3	Homo sapiens	Warfarin binds to and results in increased activity of UGT1A3 protein	affects^binding\|increases^activity	25393417
342	81-81-2	UGT1A3	Homo sapiens	[Warfarin binds to and results in increased activity of UGT1A3 protein] which results in increased glucuronidation of vorinostat	affects^binding\|increases^activity\|increases^glucuronidation	25393417
343	81-81-2	UGT1A7	Homo sapiens	Warfarin binds to and affects the activity of UGT1A7 protein	affects^activity\|affects^binding	25393417
344	81-81-2	UGT1A7	Homo sapiens	[Warfarin binds to and affects the activity of UGT1A7 protein] which affects the glucuronidation of Hymecromone	affects^activity\|affects^binding\|affects^glucuronidation	25393417
345	81-81-2	UGT1A9	Homo sapiens	Warfarin binds to and affects the activity of UGT1A9 protein	affects^activity\|affects^binding	25393417
346	81-81-2	UGT1A9	Homo sapiens	[Warfarin binds to and affects the activity of UGT1A9 protein] which affects the glucuronidation of Propofol	affects^activity\|affects^binding\|affects^glucuronidation	25393417
347	81-81-2	UGT2B17	Homo sapiens	Warfarin binds to and results in decreased activity of UGT2B17 protein	affects^binding\|decreases^activity	25393417
348	81-81-2	UGT2B17	Homo sapiens	[Warfarin binds to and results in decreased activity of UGT2B17 protein] which results in decreased glucuronidation of vorinostat	affects^binding\|decreases^activity\|decreases^glucuronidation	25393417
349	81-81-2	UGT2B7	Homo sapiens	Warfarin binds to and results in decreased activity of UGT2B7 protein	affects^binding\|decreases^activity	25393417
350	81-81-2	UGT2B7	Homo sapiens	[Warfarin binds to and results in decreased activity of UGT2B7 protein] which results in decreased glucuronidation of Zidovudine	affects^binding\|decreases^activity\|decreases^glucuronidation	25393417
351	81-81-2	USP5	Mus musculus	Warfarin results in decreased expression of USP5 mRNA	decreases^expression	20493250
352	81-81-2	VCP	Mus musculus	Warfarin results in decreased expression of VCP mRNA	decreases^expression	20493250
353	81-81-2	VCP	Mus musculus	Warfarin results in increased expression of VCP mRNA	increases^expression	20493250
354	81-81-2	VIM	Homo sapiens	Warfarin results in decreased expression of VIM protein	decreases^expression	26206560
355	81-81-2	VKORC1	Danio rerio	Warfarin results in increased expression of VKORC1 mRNA	increases^expression	25094061
356	81-81-2	VKORC1	Homo sapiens	VKORC1 3' UTR results in decreased susceptibility to Warfarin	decreases^response to substance	16676068
357	81-81-2	VKORC1	Homo sapiens	VKORC1 affects the susceptibility to Warfarin	affects^response to substance	22907842
358	81-81-2	VKORC1	Homo sapiens	VKORC1 gene affects the susceptibility to Warfarin	affects^response to substance	15630486\|19207028
359	81-81-2	VKORC1	Homo sapiens	VKORC1 gene mutant form affects the susceptibility to Warfarin	affects^response to substance	16879214\|20354686\|20553802\|20716240\|21228733\|21428138
360	81-81-2	VKORC1	Homo sapiens	VKORC1 gene mutant form results in decreased susceptibility to Warfarin	decreases^response to substance	14765194\|18266023\|25885753
361	81-81-2	VKORC1	Homo sapiens	VKORC1 gene polymorphism affects the susceptibility to Warfarin	affects^response to substance	15578879\|15930419\|16270629\|16432637\|16611750\|16847429\|16890578\|16960144\|17048007\|17049586\|17111199\|17329985\|17387222\|17391071\|17456829\|17496169\|17764537\|18370846\|18532998\|18535201\|18542936\|18574025\|18698879\|18776969\|18805772\|19018718\|19135231\|19300499\|19567378\|19998810\|20386359\|20579077\|20615525\|20842355\|21110192\|21681008\|22198820\|22528326\|22533669\|23990957\|24399734\|24474498\|24978953\|25652102\|25699611\|25747538\|26167638\|26219158\|26418980
362	81-81-2	VKORC1	Homo sapiens	VKORC1 gene polymorphism results in decreased susceptibility to Warfarin	decreases^response to substance	17961434\|18030307\|18034619\|19942260
363	81-81-2	VKORC1	Homo sapiens	VKORC1 gene SNP affects the susceptibility to Warfarin	affects^response to substance	20833655\|20854800\|21176721\|21270790\|21320153\|21321468\|21326313\|21562147\|21590310\|21635147\|21639946\|22266406\|26223945\|26257249\|26445138\|26568290\|26583785
364	81-81-2	VKORC1	Homo sapiens	VKORC1 intron polymorphism affects the susceptibility to Warfarin	affects^response to substance	15358623\|18523153
365	81-81-2	VKORC1	Homo sapiens	VKORC1 intron polymorphism results in increased susceptibility to Warfarin	increases^response to substance	16676068
366	81-81-2	VKORC1	Homo sapiens	VKORC1 intron SNP affects the susceptibility to Warfarin	affects^response to substance	18240904
367	81-81-2	VKORC1	Homo sapiens	VKORC1 polymorphism affects the susceptibility to Warfarin	affects^response to substance	17510308\|20072124\|20339978\|20637959\|21786578\|21911247\|22040439\|22161100\|22248286\|22855348\|23061746\|23167228\|23183958\|23208322\|23276529\|23279643\|23602689\|23710884\|25042728\|25312789\|26940072\|27055637
368	81-81-2	VKORC1	Homo sapiens	VKORC1 promoter polymorphism affects the susceptibility to Warfarin	affects^response to substance	18523153\|22571356
369	81-81-2	VKORC1	Homo sapiens	VKORC1 protein affects the susceptibility to Warfarin	affects^response to substance	17456829\|17995970\|19752777\|20375999\|22990331\|24750390\|27938396
370	81-81-2	VKORC1	Homo sapiens	VKORC1 protein polymorphism affects the susceptibility to Warfarin	affects^response to substance	22266406\|23800980\|24601977\|26757860
371	81-81-2	VKORC1	Homo sapiens	VKORC1 protein results in increased susceptibility to Warfarin	increases^response to substance	17049586\|17111199\|17387222\|17496169\|18532998\|18542936
372	81-81-2	VKORC1	Homo sapiens	VKORC1 protein SNP affects the susceptibility to Warfarin	affects^response to substance	23571513
373	81-81-2	VKORC1	Homo sapiens	VKORC1 results in increased susceptibility to Warfarin	increases^response to substance	20420818
374	81-81-2	VKORC1	Homo sapiens	VKORC1 SNP affects the susceptibility to Warfarin	affects^response to substance	24966969\|28079798
375	81-81-2	VKORC1	Homo sapiens	Warfarin results in decreased activity of VKORC1 protein	decreases^activity	14765194\|14765195\|18240904\|18805772\|19300499
376	81-81-2	VKORC1	Mus musculus	VKORC1 protein polymorphism results in decreased susceptibility to Warfarin	decreases^response to substance	27117082
377	81-81-2	VKORC1	Rattus norvegicus	VKORC1 protein mutant form affects the susceptibility to Warfarin	affects^response to substance	23018795
378	81-81-2	VKORC1L1	Danio rerio	Warfarin results in increased expression of VKORC1L1 mRNA	increases^expression	25094061
379	81-81-2	YWHAE	Mus musculus	Warfarin results in increased expression of YWHAE mRNA	increases^expression	20493250
380	81-81-2	ZEB1	Homo sapiens	Warfarin results in decreased expression of ZEB1 protein	decreases^expression	26206560

Serial No.	Activity Name	Details	References (PubMed)	Other details EPA (U.S)	Clinical Trials (U.S. NIH)
1				81-81-2	Warfarin

Plant Variety and Essential oils

Serial No.	Plant Name	Variety Name	Essential Oil	Compound Percentage
1	Mulethi	Mishri	Glucyrrhiza glabra mulethi essential oil

Print Back

Compound Image

2D Structure

Download

loadClass core.package

loadClass java.lang.String

loadClass core.package

JSmol exec jmolApplet0 start applet null

Jmol JavaScript applet jmolApplet0__785073267204496__ initializing

Jmol getValue debug null

Jmol getValue logLevel null

Jmol getValue allowjavascript true

AppletRegistry.checkIn(jmolApplet0__785073267204496__)

nographics false

headless false

vwrOptions:

{ "name":"jmolApplet0","allowJavaScript":true,"applet":true,"documentBase":"https://aromadb.cimapbioinfo.in/web_compound_detail.php?id=CRMOL10","platform":"J.awtjs2d.Platform","fullName":"jmolApplet0__785073267204496__","codePath":"https://aromadb.cimapbioinfo.in/jsmol/j2s/","display":"jmolApplet0_canvas2d","signedApplet":"true","appletReadyCallback":"Jmol._readyCallback","statusListener":"[J.appletjs.Jmol object]","syncId":"785073267204496","bgcolor":"#FFFFFF" }

setting document base to "https://aromadb.cimapbioinfo.in/web_compound_detail.php?id=CRMOL10"

Jmol Version: 14.2.15_2015.07.09 2015-07-09 21:14

java.vendor: Java2Script (HTML5)

java.version: 2015-07-07 14:00:27 (JSmol/j2s)

os.name: Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)

Access: ALL

memory: 0.0/0.0

processors available: 1

useCommandThread: false

appletId:jmolApplet0 (signed)

loadClass JS.ScriptManager

Jmol getValue emulate null

defaults = "Jmol"

Jmol getValue boxbgcolor null

Jmol getValue bgcolor #FFFFFF

backgroundColor = "#FFFFFF"

Jmol getValue ANIMFRAMECallback null

Jmol getValue APPLETREADYCallback Jmol._readyCallback

APPLETREADYCallback = "Jmol._readyCallback"

callback set for APPLETREADYCallback Jmol._readyCallback APPLETREADY

Jmol getValue ATOMMOVEDCallback null

Jmol getValue CLICKCallback null

Jmol getValue DRAGDROPCallback null

Jmol getValue ECHOCallback null

Jmol getValue ERRORCallback null

Jmol getValue EVALCallback null

Jmol getValue HOVERCallback null

Jmol getValue IMAGECallback null

Jmol getValue LOADSTRUCTCallback null

Jmol getValue MEASURECallback null

Jmol getValue MESSAGECallback null

Jmol getValue MINIMIZATIONCallback null

Jmol getValue SERVICECallback null

Jmol getValue PICKCallback null

Jmol getValue RESIZECallback null

Jmol getValue SCRIPTCallback null

Jmol getValue SYNCCallback null

Jmol getValue STRUCTUREMODIFIEDCallback null

Jmol getValue doTranslate null

language=en_US

Jmol getValue popupMenu null

Jmol getValue script null

Jmol getValue loadInline null

Jmol getValue load null

Jmol applet jmolApplet0__785073267204496__ ready

script 1 started

antialiasDisplay = true

FileManager.getAtomSetCollectionFromFile(admin/images/Warfarin.sdf)

FileManager opening 1 https://aromadb.cimapbioinfo.in/admin/images/Warfarin.sdf

The Resolver thinks Mol

54678486

DSViewer 3D 0

Time for openFile(admin/images/Warfarin.sdf): 308 ms

reading 39 atoms

ModelSet: haveSymmetry:false haveUnitcells:false haveFractionalCoord:false

1 model in this collection. Use getProperty "modelInfo" or getProperty "auxiliaryInfo" to inspect them.

Default Van der Waals type for model set to Babel

39 atoms created

ModelSet: not autobonding; use forceAutobond=true to force automatic bond creation

null

Script completed

Jmol script terminated

Download Sdf File Download PDB File Download MOL File

View Similar Structures (External DB)

AromaDb: A Database of Plant's Aroma Molecules

AROMA: A Database of Plant's Aroma Molecules